The price of TG Therapeutics Inc. (NASDAQ:TGTX) shares last traded on Wall Street fell -0.49% to $10.14.
Based on available information, 9 analysts follow TG Therapeutics Inc. (NASDAQ:TGTX). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $41.00 and a low of $6.00, we find $32.00. Given the previous closing price of $10.19, this indicates a potential upside of 214.03 percent. TGTX stock price is now -30.72% away from the 50-day moving average and -42.50% away from the 200-day moving average. The market capitalization of the company currently stands at $1.54B.
Among analysts, 1 rate the stock a hold while 7 rate it a buy. Brokers who have rated the stock have averaged $28.94 as their price target over the next twelve months.
With the price target reduced from $16 to $12, Goldman Upgraded its rating from Sell to Neutral for TG Therapeutics Inc. (NASDAQ: TGTX).
In other news, WEISS MICHAEL S, CEO and President bought 100,000 shares of the company’s stock on Aug 11. The stock was bought for $1,013,000 at an average price of $10.13. Upon completion of the transaction, the CEO and President now directly owns 12,073,021 shares in the company, valued at $122.42 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 23, Director Lonial Sagar sold 34,854 shares of the business’s stock. A total of $814,538 was realized by selling the stock at an average price of $23.37. This leaves the insider owning 93,878 shares of the company worth $0.95 million. Insiders disposed of 138,501 shares of company stock worth roughly $1.4 million over the past 1 year. A total of 1.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in TGTX stock. A new stake in TG Therapeutics Inc. shares was purchased by HOLOCENE ADVISORS, LP during the first quarter worth $16,483,000. RENAISSANCE TECHNOLOGIES LLC invested $5,437,000 in shares of TGTX during the first quarter. In the first quarter, CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. acquired a new stake in TG Therapeutics Inc. valued at approximately $3,322,000. CLEAR STREET LLC acquired a new stake in TGTX for approximately $3,246,000. OSSIAM purchased a new stake in TGTX valued at around $2,832,000 in the second quarter.
A candlestick chart of TG Therapeutics Inc. (NASDAQ: TGTX) showed a price of $10.19 on Friday morning. During the past 12 months, TG Therapeutics Inc. has had a low of $4.86 and a high of $35.67. As of last week, the company has a debt-to-equity ratio of 2.41, a current ratio of 2.90, and a quick ratio of 2.50. The fifty day moving average price for TGTX is $14.38 and a two-hundred day moving average price translates $17.65 for the stock.
The latest earnings results from TG Therapeutics Inc. (NASDAQ: TGTX) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.34, missing analysts’ expectations of -$0.25 by -0.09. This compares to -$0.30 EPS in the same period last year. The company reported revenue of $16.07 million for the quarter, compared to $0.59 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 2606.06 percent. For the current quarter, analysts expect TGTX to generate $50.12M in revenue.
TG Therapeutics Inc.(TGTX) Company Profile
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
